MCP-1 promoter polymorphism at -2518 is associated with metastasis of nasopharyngeal carcinoma after treatment

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6320-6326

  Tse, Ka Po ^a   Tsang, Nang Ming ^c   Chen, Kung Den ^b   Li, Hsin Pai ^b,c   Liang, Ying ^b   Hsueh, Chuen ^b,c   Chang, Kai Ping ^c   Yu, Jau Song ^b   Hao, Sheng Po ^c   Hsieh, Ling Ling ^b   Chang, Yu Sun ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MCP 1 GENE; METASTASIS; NASOPHARYNX CARCINOMA; ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CHEMOKINE CCL2; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC;

EID: 35949002836     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1029     Document Type: Article

References (47)

1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. Volume VII. IARC Sci Publ 1997;143:814-5.
2. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970;228:1056-8.
3. Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998;83:582-8.
4. Su CK, Wang CC. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2002;54:752-8.
5. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54.
6. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-51.
7. Grulich AE, McCredie M, Coates M. Cancer incidence in Asian migrants to New South Wales, Australia. Br J Cancer 1995;71:400-8.
8. Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002;31:395-9.
9. Cho EY, Hildesheim A, Chen CJ, et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 2003;12:1100-4.
10. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344-8.
11. Lu B, Rutledge BJ, Gu L, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1 - deficient mice. J Exp Med 1998;187:601-8.
12. Gu L, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. Chem Immunol 1999;72:7-29.
13. Szalai C, Kozma GT, Nagy A, et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001;108:375-81.
14. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001;158:233-9.
15. Gonzalez-Escribano MF, Torres B, Aguilar F, et al. MCP-1 promoter polymorphism in Spanish patients with rheumatoid arthritis. Hum Immunol 2003;64:741-4.
16. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989;169:1449-59.
17. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.
18. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998;194:335-40.
19. Ohta M, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002;102:220-4.
20. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 2005;11:7629-36.
21. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-9.
22. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63:7451-61.
23. Dehqanzada ZA, Storrer CE, Hueman MT, et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006;12:478-86.
24. Tang KF, Tan SY, Chan SH, et al. A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol 2001;32:42-9.
25. Sobin LH, Wittekind C. International Union against Cancer. TNM: classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
26. Shanmugaratnam K. Histological typing of nasopharyngeal carcinoma. IARC Sci Publ 1978. p. 3-12.
27. Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, Rickinson AB. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 1992;140:879-87.
28. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005;15:417-25.
29. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κB and AP-1. Eur J Immunol 1997;27:1091-7.
30. + T cells. Cancer Res 1999;59:1599-605.
31. Sham JS, Choy D. Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br J Radiol 1990;63:51-8.
32. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 2002;99:13795-800.
33. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006;28:293-307.
34. Seymour K, Pettit S, O'Flaherty E, Charnley RM, Kirby JA. Selection of metastatic tumour phenotypes by host immune systems. Lancet 1999;354:1989-91.
35. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-11.
36. Hunter K. Host genetics influence tumour metastasis. Nat Rev 2006;6:141-6.
37. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006;8:R16.
38. Kurniawan AN, Susworo R, Sumanto. Nasopharyngeal carcinoma: correlation of histopathology with radiation response. Southeast Asian J Trop Med Public Health 1985;16:613-8.
39. Tan BC, Khor TH, Chia KB. Radiotherapy in treatment of nasopharyngeal carcinoma. Ann Acad Med Singapore 1980;9:347-9.
40. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992;23:271-80.
41. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452-5.
42. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9.
43. Lin J, Wang W, Chen K, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
44. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24:5414-8.
45. Caselli E, Fiorentini S, Amici C, Di Luca D, Caruso A, Santoro MG. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1 - dependent capillary-like structure formation: role of the IKK/NF-κB pathway. Blood 2007;109:2718-26.
46. Gaudreault E, Fiola S, Olivier M, Gosselin J. Epstein-Barr virus induces Mcp-1 secretion by human monocytes via Tlr2. J Virol 2007;81:8016-24.
47. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003;10:490-504.